Literature DB >> 26059827

Drug-induced Skin Lesions in Cynomolgus Macaques Treated with Metabotropic Glutamate Receptor 5 (mGluR5) Negative Allosteric Modulators.

Gopinath S Palanisamy1, John M Marcek2, Gregg D Cappon2, Jessica Whritenour2, Christopher L Shaffer3, Joseph T Brady2, Christopher Houle4.   

Abstract

Three orally administered metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulators caused skin lesions consistent with delayed type-IV hypersensitivity in cynomolgus macaques in 2- and 12-week toxicity studies. Several monkeys developed macroscopic skin lesions in multiple locations after 8 to 9 days of dosing; the most prominent effects involved the genital region of males and generalized erythema occurred in both sexes. Microscopic lesions occurred in both clinically affected and unaffected areas and were characterized by lymphocytic interface inflammation, subepidermal bullae, and individual keratinocyte vacuolation/necrosis. In the 12-week study, clinical effects in 2 animals resolved with continued dosing, whereas in others the inflammatory process progressed with 1 female exhibiting systemic lymphocytic inflammation in multiple tissues. The inflammatory infiltrate consisted of CD3 and CD4 positive T lymphocytes with minimal CD68 positive macrophages and only rare CD8 positive T lymphocytes. A subset of animals given a dosing holiday was subsequently rechallenged with similar lesions developing but with a more rapid clinical onset. These skin lesions were consistent with type-IV delayed hypersensitivity with some features comparable to bullous drug eruptions in humans. A relationship between these findings and the intended mode of action for these compounds could not be ruled out, given the occurrence across different chemotypes.
© 2015 by The Author(s).

Entities:  

Keywords:  Parkinson’s disease; adverse drug reactions; macaques; metabotropic glutamate receptor 5 (mGluR5); skin lesions; type-IV hypersensitivity

Mesh:

Substances:

Year:  2015        PMID: 26059827     DOI: 10.1177/0192623315588114

Source DB:  PubMed          Journal:  Toxicol Pathol        ISSN: 0192-6233            Impact factor:   1.902


  3 in total

Review 1.  Metabotropic Glutamate Receptor 5 as a Target for the Treatment of Depression and Smoking: Robust Preclinical Data but Inconclusive Clinical Efficacy.

Authors:  Samuel A Barnes; Douglas J Sheffler; Svetlana Semenova; Nicholas D P Cosford; Anton Bespalov
Journal:  Biol Psychiatry       Date:  2018-03-09       Impact factor: 13.382

2.  Identification of MHC Haplotypes Associated with Drug-induced Hypersensitivity Reactions in Cynomolgus Monkeys.

Authors:  Hong Wu; Jessica Whritenour; Jonathan C Sanford; Christopher Houle; Karissa K Adkins
Journal:  Toxicol Pathol       Date:  2016-11-23       Impact factor: 1.902

3.  Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation.

Authors:  Andrew S Felts; Alice L Rodriguez; Anna L Blobaum; Ryan D Morrison; Brittney S Bates; Analisa Thompson Gray; Jerri M Rook; Mohammed N Tantawy; Frank W Byers; Sichen Chang; Daryl F Venable; Vincent B Luscombe; Gilles D Tamagnan; Colleen M Niswender; J Scott Daniels; Carrie K Jones; P Jeffrey Conn; Craig W Lindsley; Kyle A Emmitte
Journal:  J Med Chem       Date:  2017-05-31       Impact factor: 7.446

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.